Nanoparticle-Aptamer Bioconjugates
暂无分享,去创建一个
Omid C. Farokhzad | Sangyong Jon | Ali Khademhosseini | Thanh-Nga T Tran | David A Lavan | Robert Langer | Sangyong Jon | Ali Khademhosseini | Thanh-Nga T. Tran | David A. LaVan | Robert Langer
[1] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.
[2] B. Hicke,et al. Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.
[3] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[4] S. Vinores. Technology evaluation: pegaptanib, Eyetech/Pfizer. , 2003, Current opinion in molecular therapeutics.
[5] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.
[6] T. Zhang,et al. Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.
[7] F. Leach. Targeting Prostate Specific Membrane Antigen in Cancer Therapy: Can Molecular Medicine Be Brought to the Surface? , 2004, Cancer biology & therapy.
[8] N. Bander,et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.
[9] D. Bostwick,et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.
[10] O. Ludkovski,et al. Stabilized plasmid-lipid particles for systemic gene therapy. , 2000, Gene therapy.
[11] L. Gold,et al. Aptamers as therapeutic and diagnostic agents. , 2000, Journal of biotechnology.
[12] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[13] Robert Langer,et al. Drugs on Target , 2001, Science.
[14] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[15] N. Bander,et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.
[16] I. Maclachlan,et al. Stabilized plasmid-lipid particles: a systemic gene therapy vector. , 2002, Methods in enzymology.
[17] D. S. Coffey,et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. , 2002, Cancer research.
[18] W. Fair,et al. Expression of the prostate-specific membrane antigen. , 1994, Cancer research.
[19] K. Maruyama,et al. Intracellular targeting therapy of cisplatin‐encapsulated transferrin‐polyethylene glycol liposome on peritoneal dissemination of gastric cancer , 2002, International journal of cancer.
[20] J. Visser,et al. Measurement of intracellular (compartmental) pH by 31P NMR in Aspergillus niger. , 2000, Journal of biotechnology.
[21] R. Langer,et al. Drug delivery and targeting. , 1998, Nature.
[22] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[23] R Langer,et al. Drug delivery. Drugs on target. , 2001, Science.
[24] Louis M Weiner,et al. New approaches to antibody therapy , 2000, Oncogene.